The goal of this clinical trial is to learn if the pilot intervention of CYP2C19 genotype-guided antiplatelet therapy works to reduce the occurrence of cardiovascular events after Percutaneous Coronary Intervention (PCI) done in coronary artery disease patients. It will also learn about the comparison between clopidogrel and ticagrelor.
The main questions it aims to answer are:
To compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on platelet reactivity.
To compare the impact of CYP2C19 genotype-guided antiplatelet therapy, universal use of clopidogrel and ticagrelor treatment on the risk of major adverse cardiovascular events (MACE) among newly recruited stable CAD patients.
Participants will:
Take drug clopidogrel or ticagrelor, based on the random group allocation every day for 1 month. One group of patients will undergone CYP2C19 genetic test for genotype-guided antiplatelet therapy, whether clopidogrel or ticagrelor.
Visit the clinic post 30 days of PCI for follow-ups and platelet function tests.
Males or females
Aged between 18 to 80 years old
Patients presents with stable CAD or acute coronary syndrome (ACS)
Eligible for percutaneous coronary intervention (PCI)
Primary PCI or rescue PCI
Any urgent/emergent coronary angiography procedure that would not allow for genetic testing to be performed before PCI
Failure of index PCI
Patient or physician refusal to enroll in the study
Nur Hafizah Annezah binti Utuh
Lead sponsor
Universiti Sains Malaysia
Sponsor institution